Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun Pharma Kite Biotechnology Co. Ltd.

Latest From Fosun Pharma Kite Biotechnology Co. Ltd.

The Many Layers Of EOS Imaging – Surgical Planning, Low-Dose Imaging, 3D Services

EOS imaging launched its web-based 3D surgical planning software at the AAOS conference, the biggest annual gathering of orthopedic surgeons. Medtech Insight takes a closer look at EOS's marketing plans as well as its other services and products, including its core product: a low-dose, full-body and stereo-radiographic imaging system that scans patients in the standing position. It's used in the US by several radiologists to monitor pediatric patients.

Orthopedics Innovation

China's Draft Cell Therapy Guidelines Draws Concern From Industry

New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.

China Gene Therapy

A Wild CAR-T Race In China: The Hype, Reality And What Works

As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.

China Clinical Trials

Glycotest Attracts $10M Chinese Investment For Liver Disease Test

Liver-diagnostics firm Glycotest has secured a $10m investment from Chinese healthcare group Shanghai Fosun Pharmaceutical (Fosun Pharma) to drive commercialization of its HCC Panel test for early-stage liver cancer.

Financing Liver & Hepatic
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Fosun Pharma Kite Biotechnology Co. Ltd.
  • Senior Management
  • Contact Info
  • Fosun Pharma Kite Biotechnology Co. Ltd.
    Shanghai,
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register